Enbrel® helps patients across all its indications stay on treatment long term1-5
Long-term disease control and sustained drug survival for up to 12 years1
Juvenile Idiopathic Arthritis
Demonstrated positive treatment outcomes for up to 10 years2
Significant improvements in disease activity and function across all stages of the disease for up to 7 years3
Sustained efficacy and drug survival for up to 5.5 years4
Sustained drug survival for up to 7.5 years5
axSpA, axial spondyloarthritis; JIA, juvenile idiopathic arthritis; PsA, psoriatic arthritis; PsO, psoriasis; RA, rheumatoid arthritis.
Please click the Prescribing Information link to view the safety and adverse events information of Enbrel®.
For the use only of Registered Medical Practitioners or a Hospital or a Laboratory.
PP-ENB-IND-0814 August 2022
These pages are not intended for patients or for members of the general public. The web pages contain promotional content.
If you select 'No', you will be redirected to Pfizer.co.in
For more details on, Who is a Registered Medical Practitioner*, please visit
https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf , Page No. 39, Rule 2 part (ee), last accessed on 13th September 2019.
Address: The Capital, A Wing, 1802, 18th Floor, Plot No. C-70, 'G' Block, Bandra Kurla Complex, Bandra East, Mumbai - 400051.
PP-UNP-IND-0012 July 2022